Pharmaceutical - Cardio-vascular, Sanofi

Filter

Current filters:

Cardio-vascularSanofi

Popular Filters

1 to 25 of 34 results

Sanofi and MyoKardia ink deal for genetic heart disease research

Sanofi and MyoKardia ink deal for genetic heart disease research

17-09-2014

French pharma major Sanofi has signed a global collaboration with privately-held US firm MyoKardia to…

Cardio-vascularGlobalLicensingMyoKardiaPharmaceuticalResearchSanofi

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

Sanofi and Regneron say Phase III alirocumab trials met primary endpoint

30-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals have announced that nine…

alirocumabCardio-vascularGeorge YancopoulosPharmaceuticalResearchSanofiUSA

Acute coronary syndrome treatment market to more than triple by 2023

Acute coronary syndrome treatment market to more than triple by 2023

30-07-2014

The launch of several drugs with “extraordinary blockbuster potential” will cause the acute coronary…

Acute coronary syndromealirocumabAmgenBayerCardio-vascularEuropeevolocumabJapanMarkets & MarketingMerck & CoPfizerPharmaceuticalSanofiUSAXareltoZontivity

FDA probing Regeneron and Sanofi’s investigational drug alirocumab

FDA probing Regeneron and Sanofi’s investigational drug alirocumab

10-03-2014

French drug major Sanofi has revealed in a regulatory filing that the US Food and Drug Administration…

alirocumabCardio-vascularNorth AmericaPharmaceuticalRegeneronRegulationResearchSanofiUSA

Sanofi to collaborate with the ACC to recruit patients for alirocumab clinical trial

Sanofi to collaborate with the ACC to recruit patients for alirocumab clinical trial

19-12-2013

French drug major Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) have announced…

Cardio-vascularPharmaceuticalResearchSanofiUSA

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

Sanofi’s alirocumab monotherapy reduced LDL cholesterol three times more than ezetimibe

16-10-2013

Sanofi and partner Regeneron Pharmaceuticals this morning released results from the Phase III ODYSSEY…

BiotechnologyCardio-vascularPharmaceuticalRegeneronResearchSanofi

Sanofi strengthens its presence in Algeria with €70 million investment

Sanofi strengthens its presence in Algeria with €70 million investment

26-09-2013

French drug major Sanofi revealed today that construction has begun on its new Sidi Abdellah industrial…

Cardio-vascularDiabetesFinancialPharmaceuticalProductionRest of the WorldSanofi

Sanofi US in deal to commercialize PA8140/PA32540

04-09-2013

The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

FDA should warn against prolonged use of Plavix for stent patients, says US consumer group

21-08-2013

The US Food and Drug Administration should warn patients and doctors that taking the widely prescribed…

Bristol-Myers SquibbCardio-vascularNorth AmericaPharmaceuticalPlavixRegulationSanofi

Negative late-stage trial results for Sanofi's iniparib and otamixaban

03-06-2013

There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as…

BiotechnologyCardio-vasculariniparibOncologyotamixabanPharmaceuticalResearchSanofi

Sanofi plans acceleration of expansion into Ukraine this year

07-05-2013

French drug major Sanofi (Euronext: SAN) is considering expanding its presence in Ukraine this year,…

Cardio-vascularDiabetesEuropeMarkets & MarketingPharmaceuticalProductionSanofi

FDA clears Sanofi and Isis' Kynamro for inherited cholesterol disorder

30-01-2013

The US Food and Drug Administration yesterday approved Sanofi (Euronext: SAN) subsidiary Genzyme's orphan…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Sanofi and Regeneron recruiting patients for cardiovascular outcomes trial with antibody to PCSK9 for hypercholesterolemia

05-11-2012

French drug major Sanofi (Euronext: SAN) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) say…

BiotechnologyCardio-vascularPharmaceuticalRegeneronREGN727ResearchSanofiSAR236553

FDA advisory panel votes 9 to 6 to approve Genzyme's Kynamro

19-10-2012

The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory yesterday voted by…

BiotechnologyCardio-vascularGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRare diseasesRegulationSanofi

Anti-clotting drugs prasugrel and clopidogrel yield similar results

27-08-2012

The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

Sanofi pulls European and other regulatory filings for Mulsevo

10-07-2012

The European Medicines Agency says it has been formally notified by French drug major Sanofi (Euronext:…

Cardio-vascularEuropeMulsevoNorth AmericaPharmaceuticalRegulationSanofisemuloparin

Isis earns $25 million milestone from Genzyme as US FDA accepts Kynamro NDA

31-05-2012

The US Food and Drug Administration has accepted for filing the New Drug Application for Kynamro (mipomersen…

BiotechnologyCardio-vascularFinancialGenzymeIsis PharmaceuticalsKynamroNorth AmericaPharmaceuticalRegulationSanofi

Positive results for Regeneron and Sanofi's SAR236553/REGN727

27-05-2012

USA-based Regeneron (Nasdaq: REGN) and French drug major Sanofi (Euronext: SAN) presented results of…

BiotechnologyCardio-vascularPharmaceuticalRegeneronResearchSanofi

1 to 25 of 34 results

Back to top